Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
69 results about "Oxyntomodulin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oxyntomodulin (often abbreviated OXM) is a naturally occurring 37-amino acid peptide hormone found in the colon, produced by the oxyntic (fundic) cells of the oxyntic (fundic) mucosa. It has been found to suppress appetite.
Oxyntomodulin Derivatives
ActiveUS20100144617A1Present inventionPeptide/protein ingredientsMetabolism disorderDiseaseDiabetes mellitus
Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.
Owner:MSD ITAL +1
Recombinant oxyntomodulin (OXM) fusion protein, and preparation and application thereof
InactiveCN102010473AExtended half-lifeImprove stabilityPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseRecombinant expression
The invention relates to long-acting and stable oxyntomodulin (OXM). An Fc segment of human immunoglobulin G and the human OXM form fusion protein through a connecting peptide. A method for preparing the fusion protein comprises the following steps of: preparing the human OXM and an Fc segment gene of the human immunoglobulin respectively, and connecting the human OXM and the Fc segment gene of the human immunoglobulin to construct connecting segment-containing recombinant expression vectors; and transforming host cells by using the recombinant expression vectors, culturing the host cells and recovering from cell culture and purifying the host cells to obtain the recombinant fusion protein. The fusion protein can be used for preparing medicaments for treating metabolic diseases such as diabetes and obesity.
Owner:曹鹏 +1
Modification of Feeding Behaviour
InactiveUS20080064636A1Reduce weightIncreased energy expenditurePeptide/protein ingredientsMetabolism disorderEnergy expenditureBiology
The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and / or increase energy expenditure.
Owner:IMPERIAL INNOVATIONS LTD
Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
ActiveUS7928058B2Present inventionPeptide/protein ingredientsMetabolism disorderDiabetes mellitusBody weight
Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.
Owner:MSD ITAL +1
Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
ActiveUS20140212440A1Reduces food intakeSuppresses gastric emptyingPeptide/protein ingredientsMetabolism disorderSide effectReceptor activation
The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
Owner:HANMI SCI CO LTD
Novel glp-1 receptor stabilizers and modulators
Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and / or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP (1-42), PTH (1-34), Glucagon (1-29), GLP-2 (1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants.
Owner:RECEPTOS LLC
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
ActiveUS20140128318A1Reduces food intakeSuppresses gastric emptyingCell receptors/surface-antigens/surface-determinantsSugar derivativesSide effectReceptor activation
The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
Owner:HANMI SCI CO LTD
Chemosensory Receptor Ligand-Based Therapies
Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.
Owner:AMBRA BIOSCI LLC
Long-acting oxyntomodulin variants and methods of producing same
ActiveUS20150072924A1Improving biological half lifeIncrease the areaPeptide/protein ingredientsAntibody mimetics/scaffoldsAgonistPeptide
This invention is directed to a chorionic gonadotrophin carboxy terminal peptide (CTP) modified dual GLP-1 / Glucagon receptor agonist, and methods of producing and using the same. In one embodiment, the present invention provides a CTP-modified polypeptide comprising a dual GLP-1 / Glucagon receptor agonist and at least one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus or carboxy terminus of said agonist.
Owner:OPKO BIOLOGICS
Transformant for reducing weight and fat and preparation method thereof
InactiveCN101608172AGood curative effectOvercome costsBacteriaMetabolism disorderBifidobacteriumProkaryotic expression
The invention relates to a transformant for reducing weight and fat, which is obtained by converting recombinant expression plasmids of a human gastric acid regulin gene into probiotic bacteria of human beings or animals, wherein the recombinant expression plasmids of the human gastric acid regulin gene are obtained by cloning a genetic fragment for coding human gastric acid regulin to an expression area of prokaryotic expression plasmids taking an ara operon as a promoter; and the probiotic bacteria of human beings or animals are bifidobacteria or lactic acid bacteria. The transformant can induce, express and excrete gastric acid regulin inside and outside intestinal tracts through revulsant L, namely, arabinose or low-polyxylose and plays a role of reducing weight and fat, therefore, the transformant can be prepared into an oral live bacterial preparation for reducing weight and fat.
Owner:SOUTHERN MEDICAL UNIVERSITY
Oxyntomodulin analogues and their effects on feeding behaviour
InactiveUS20150011467A1Reduced food intakeGood effectPeptide/protein ingredientsMetabolism disorderC-terminusAmino acid
Compounds of the invention are novel peptide analogues of oxyntomodulin (oxm) in which one or more amino acids of the oxm sequence have been changed. Changing amino acids 15-24 of oxm to either amino acids 968-977 of the α-latrotoxin peptide (and variations thereof) or amino acids 15-24 of exendin-4 (and variations thereof), or combinations of sequences from these sources, and / or changing amino acids 27-33 of oxm to amino acids 27-33 of exendin-4, and / or the addition of amino acids to the C-terminus of the peptide, results in a series of analogues of oxm that demonstrate the oxm like activity of reducing food intake, and with certain embodiments a greater ability to decrease food intake.
Owner:IMPERIAL INNOVATIONS LTD
Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
ActiveUS9731031B2Reduces food intakeSuppresses gastric emptyingPeptide/protein ingredientsMetabolism disorderSide effectReceptor activation
The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
Owner:HANMI SCI CO LTD
Long acting proteins and peptides and methods of making and using the same
ActiveUS20100121032A1Antibacterial agentsPeptide/protein ingredientsPolyethylene glycolGlucagon-like peptide-1
Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
Owner:BOLDER BIOTECH
Methods of making proteins and peptides containing a single free cysteine
ActiveUS8617531B2Antibacterial agentsPeptide/protein ingredientsCysteine thiolatePolyethylene glycol
Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
Owner:BOLDER BIOTECH
Oxyntomodulin (OXM) analogue and application thereof
InactiveCN106986924AHigh activityConvenient purification workPeptide-nucleic acidsPeptide/protein ingredientsSynthesis methodsFreeze-drying
The invention relates to a novel oxyntomodulin (OXM) analogue and a synthesis method thereof. A terminal C of natural OXM is subjected to Ex-4, GLP-1 and Lixisenatide partial terminal C peptide sequence substitution to obtain the OXM analogue with optimal pharmacological activity, synthesis of a peptide chain is rapidly implemented by an orthogonal protection strategy solid phase synthesis method, a coarse product is purified and freeze-dried to obtain the OXM analogue.
Owner:CHINA PHARM UNIV
Pegylated oxm variants
ActiveUS20150258208A1Peptide/protein ingredientsMetabolism disorder9-fluorenylmethoxycarbonylPharmacology
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.
Owner:OPKO BIOLOGICS
GLP-1 receptor stabilizers and modulators
Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and / or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants.
Owner:RECEPTOS LLC
Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
ActiveUS9724420B2Weight optimizationImprove physiological activityPeptide/protein ingredientsAntibody mimetics/scaffoldsAlcohol sugarsIn vivo
Owner:HANMI PHARMA
A composition for treating diabetes or diabesity comprising oxyntomodulin analog
InactiveUS20150299282A1High activityEasy to usePeptide/protein ingredientsMetabolism disorderNormal blood glucoseDiabetic complication
Disclosed are a composition for preventing or treating diabetes, diabesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.
Owner:HANMI PHARMA
Oxyntomodulin analogue
ActiveUS20170183383A1Cosmetic preparationsPeptide-nucleic acidsDiabetes mellitusAdverse drug reaction
Provided is an oxyntomodulin analogue. The analogue comprises GCGR and GLP-1R dual agonist activity, improved enzymolysis stability and biological activity, and no adverse reactions. The analogue can be used to prepare medication for treating hyperphagia, obesity and diabetes.
Owner:JIANG XIANXING
Long-acting hypoglycemic weight-reducing peptide as well as preparation method and application thereof as medicine
ActiveCN109232743AIncreased alanine aminotransferase levelsAlanine aminotransferase levels decreasedPeptide/protein ingredientsMetabolism disorderPharmacologic actionChemical compound
The invention relates to a long-acting hypoglycemic weight-reducing oxyntomodulin (OXM) hybrid peptide as well an application and a synthesis method thereof. By changing a peptide sequence of OXM andhybridizing with a peptide sequence of Exenatide, an OXM hybrid peptide with longer pharmacological action time and better weight loss effect is obtained. The synthesis of a target polypeptide is rapidly realized through a solid-phase synthesis method of an orthogonal protection strategy, and a crude product is purified and lyophilized to obtain a target compound.
Owner:CHINA PHARM UNIV
Long-acting oxyntomodulin (OXM) hybrid peptide as well as preparation method and application thereof
ActiveCN108948212AIn line with pathological featuresEffective in treating non-alcoholic fatty liver diseasePeptide/protein ingredientsMetabolism disorderPharmacologic actionFreeze-drying
The invention relates to a class of long-acting oxyntomodulin (OXM) hybrid peptides as well as application and synthetic methods of the hybrid peptides. The preparation method comprises the followingsteps: modifying the OXM, hybridizing with a peptide sequence of Exenatide, and conjugating fatty acid chains, thereby obtaining the OXM hybrid peptides with long pharmacologic action time and excellent weight losing effects. Synthesis of target polypeptides is rapidly realized by an orthogonal protection strategy solid-phase synthesis method, and the crude product is purified and freeze-dried soas to obtain the target compound.
Owner:CHINA PHARM UNIV
GLP-1 receptor stabilizers and modulators
Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and / or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.
Owner:RECEPTOS LLC
Composition for treating hyperlipidemia comprising oxyntomodulin derivative
ActiveUS9901621B2Improve activation abilityLower Level RequirementsConnective tissue peptidesPeptide/protein ingredientsHyperlipidemiaGlucagon receptor
The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol / low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.
Owner:HANMI PHARMA
Composition for treating hyperlipidemia comprising oxyntomodulin derivative
InactiveUS20150182593A1Improve activation abilityIncreasing high-density cholesterol levelPeptide/protein ingredientsAlbumin peptidesBULK ACTIVE INGREDIENTGlucagon receptor
The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol / low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.
Owner:HANMI PHARMA
Pegylated oxm variants
ActiveUS20150148289A1Peptide/protein ingredientsMetabolism disorder9-fluorenylmethoxycarbonylPharmacology
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.
Owner:OPKO BIOLOGICS
Conjugate Comprising Oxyntomodulin And An Immunoglobulin Fragment, And Use Thereof
ActiveUS20170340753A1Maintain activityExtended half-lifePeptide/protein ingredientsAntibody mimetics/scaffoldsSide effectReceptor activation
Owner:HANMI SCI CO LTD
Composition for treating hyperlipidemia comprising oxyntomodulin derivative
ActiveUS20160199451A1Improve activation abilityLower Level RequirementsPeptide/protein ingredientsAlbumin peptidesBULK ACTIVE INGREDIENTGlucagon receptor
The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol / low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.
Owner:HANMI PHARMA
Oxyntomodulin peptide analogue
ActiveCN102740873AReduce intakeLittle side effectsPeptide/protein ingredientsMetabolism disorderDiabetes mellitusObesity
The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and / or obesity.
Owner:ELI LILLY & CO
Pegylated oxm variants
ActiveUS20150119320A1Increase the areaReduce dosing frequencyPeptide/protein ingredientsMetabolism disorder9-fluorenylmethoxycarbonylPharmacology
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.
Owner:OPKO BIOLOGICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com